Analyst Ratings For Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Today, Oppenheimer set its price target on Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to $100.00 per share.
There are 4 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is Hold with a consensus target price of $108.25 per share, a potential 36.15% upside.
Some recent analyst ratings include
- 8/8/2018-Enanta Pharmaceuticals Inc (NASDAQ:ENTA) gets downgraded to Market Perform by UBS Group
- 7/31/2018-Enanta Pharmaceuticals Inc (NASDAQ:ENTA) had its Buy rating reiterated by JMP Securities with a $120.00 price target
- 6/6/2018-Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has coverage initiated with a Buy rating and $133.00 price target
- 4/4/2018-Enanta Pharmaceuticals Inc (NASDAQ:ENTA) had its Hold rating reiterated by Royal Bank of Canada with a $80.00 price target
- 2/8/2018-Enanta Pharmaceuticals Inc (NASDAQ:ENTA) gets downgraded to Neutral by JPMorgan Chase & Co.
- On 10/1/2018 Tim Ocain, Insider, sold 25,000 with an average share price of $83.64 per share and the total transaction amounting to $2,091,000.00.
- On 9/20/2018 Nathalie Adda, VP, sold 4,155 with an average share price of $95.32 per share and the total transaction amounting to $396,054.60.
- On 8/20/2018 Nathalie Adda, VP, sold 4,155 with an average share price of $92.32 per share and the total transaction amounting to $383,589.60.
- On 7/18/2018 Nathalie Adda, VP, sold 5,045 with an average share price of $124.84 per share and the total transaction amounting to $629,817.80.
- On 7/6/2018 Jay R Luly, Insider, sold 35,000 with an average share price of $125.24 per share and the total transaction amounting to $4,383,400.00.
- On 6/18/2018 Nathalie Adda, VP, sold 4,155 with an average share price of $114.85 per share and the total transaction amounting to $477,201.75.
- On 6/11/2018 Paul J Mellett, Treasurer, sold 15,000 with an average share price of $120.57 per share and the total transaction amounting to $1,808,550.00.
About Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Recent Trading Activity for Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Shares of Enanta Pharmaceuticals Inc closed the previous trading session at 78,39 −3,52 4,30 % with 81.91 shares trading hands.